Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
News|Articles|February 10, 2022
- Pharmaceutical Technology's In the Lab eNewsletter, March 2022
- Volume 17
- Issue 3
European Patent Office Grants Further Patent to Salipro Biotech
Author(s)Pharmaceutical Technology Editors
The European Patent Office has granted another patent to Salipro Biotech, covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.
Advertisement
The European Patent Office has granted another patent to Salipro Biotech, a Swedish biotech company, covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.
According to a Feb. 8, 2022 press release, the “Antigen and method for production thereof” patent (No. EP 3 043 814 B1) will strengthen Salipro Biotech’s proprietary platform technologies to enable the discovery and development of next-generation therapeutics against challenging drug targets.
“We’re constantly increasing our collaborations, partnerships and licensing agreements with major pharma companies on a wide range of challenging drug targets,” said Maria Knudsen, business development director at Salipro Biotech AB, in the press release. “Expanding our already strong patent portfolio further will enable us to increase the value of such collaborations for our partners as well as moving towards building our own discovery pipeline.”
“We’re excited about this important milestone that provides additional protection for our core technologies. The market for therapeutic antibodies, vaccines and biologics is ever expanding,” added Jens Frauenfeld, CEO, Salipro Biotech, in the press release. “Securing these patents protects our innovative platform and further strengthens our position by supplementing our foundational and follow-up patents that have already been granted to Salipro Biotech in many countries, including US, [European Union], China, and Japan.”
Source:
Articles in this issue
over 4 years ago
A Look at Managing Increased Data Output Through Automationover 4 years ago
Lab Operations Improvementsover 4 years ago
Taconic Biosciences Launches Cage+ Contract Breeding Serviceover 4 years ago
PETA Science Group Shares Goals With New FDA Commissionerover 4 years ago
FDA to Hold Public Symposium on Multi-Identification BiomarkersAdvertisement
Related to this article
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement